Kura Oncology

United States
San Diego, California, United States, 92037

Company profile

Kura Oncology company profile

At Kura Oncology, They are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how they treat cancer. They now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. This new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. They are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Their development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.

Business identity

Contact email
[email protected]
Phone number
858-500-8835
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2014-01-01, Year

Headquarters

Postal code
92037
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
12
Total equity funding
$1.1B
Last funding
Post IPO Equity / $150M / 2024-01-24
Last equity funding
Post IPO Equity / $150M
Investors
12
Lead investors
3
Founders
4
Articles
288
Exited on
2015-09-22

Founders and investors

Founders

Antonio GualbertoPingda RenTroy WilsonYi Liu

Lead investors

Bristol-Myers SquibbEcoR1 CapitalHercules Capital

Investors

ARCH Venture PartnersDeerfield ManagementFidelityHercules CapitalOUP (Osage University Partners)